Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that it enclosed copies of the newspaper advertisement published on September 08, 2023, intimating the dispatch of Notice of 35th Annual General Meeting and Annual Report for the financial year 2022-2023 for convening the 35th Annual General Meeting to be held on Saturday, September 30, 2023 at 10.00 am (IST) through Video Conferencing or Other Audio-Visual Means, without physical presence of the members at a common venue, in compliance with the Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 21/2021, 2/2022 and 10/2022 dated 08th April, 2020, 13th April, 2020, 05th May, 2020, 13th January, 2021, 14th December, 2021, 05th May, 2022 and 28th December, 2022, respectively, issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) Circular Nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79, SEBI/HO/CFD/CMD2/CIR/P/2022/62 and SEBI/HO/CFD /PoD-2/P/CIR/2023/4 dated 12th May, 2020, 13th May, 2022 and 05th January , 2023, respectively. The advertisement has published in the newspapers: Financial Express (in English language) and Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors section.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: